Welcome to Medira Ltd, the company that specialises in a unique range of biomaterials.

Medira specialises in natural biomaterials to aid tissue regeneration.

Our goal is to provide market-leading products with the type of support that our discerning customers expect from suppliers.

  • A detailed understanding of the science behind our products, and
  • Why this will provide optimal outcomes for your patients

Because we review the research before sourcing any product, our customers have come to trust that Medira will never let them down.

Medira is a certified ISO9001:2015 company, Our Quality Management System policy can be read here.

Formed in 2008 as a consultancy, morphing into major biomaterials supplier, our team has extensive knowledge of tissue regeneration and healing and a clear understanding of the application of our products. From our head-office in Cambridge we can support the large-scale supplier and the smaller user.

Our regenerative biomaterials

Medira’s Platelet Rich Plasma (PRP) brand names

  • For non-surgical aesthetics, the brand name is Cellenis® PRP  (Eclipse PRP in the US)
  • For surgical applications, such as ortho/sports med, dental, oral max fac, ENT, plastics and wound healing, the brand name is Tropocells® PRP

Medira stocks both Cellenis® and Tropocells® brands whether PRP or PRF – identical product and price.   Both Cellenis® and Tropocells® use the latest, advanced and patented gel separation technology which meets or exceeds high regulatory and manufacturing controls.

Looking at PRP literature as a whole, a clear pattern is apparent. Combining studies in which a poor-quality PRP is used with studies in which a high-quality PRP is used dilutes the net positive effect. When taken together, it is natural to conclude that evidence is insufficient.

However, the experts suggest a different conclusion:

Not all PRP is created equal.


Once the cellular profile of PRP is understood, the literature finally makes sense:

  1. Recent advancements in our scientific understanding outline which components in whole blood augment PRP’s healing potential and which ones inhibit it.
  2. The components of an ideal PRP formulation are now better understood.
  3. Looking over the literature, experts can see why some studies showed that PRP was ineffective-the PRP used was far from ideal.
  4. Recent publications in which a more ideal PRP formulation was used achieved positive results.
  5. Because this optimal formulation has not been standardized, systemic reviews of the literature cannot exclude the suboptimal formulations without being judged of bias; therefore, many reviews have inconclusive results.

Our understanding of how platelets function and how neighboring cells influence their function, has increased dramatically. We now know that red blood cells (RBCs) and neutrophils have an inflammatory and catabolic (degrading) effect within the treatment area and inhibit the healing process.1 In contrast, monocytes and lymphocytes have an anabolic (regenerative) effect within the treatment area and enhance the platelets’ ability to heal.2

What Is the Ideal PRP Formulation?

  • A dose of platelets large enough to create a healing response
  • Minimising RBCs
  • Minimising neutrophils
  • Maximising monocytes
  • Maximising lymphocytes

References for ldeal PRP Formulation:

1   Amabie PR, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther, 2013 Jun 7; 4(3):67,

Yoshida R, et al. Increasing platelet concentration in platelet-rich plasma inhibits anterior cruciate ligament cell function in three-dimensional culture. J Ortho Res 32, 291, 2014

Assmus B, et al.  Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy 2010

Sethi D. et al Bone Marrow Concentrate for Treatment of Knee Osteoarthritis: A Mini Review. J Orthop Ther JORT-191.2018

2   Lana J, et al. Contributions for classification of platelet rich plasma – proposal of a new classification: MARSPILL, Regenerative Medicine 12:5, 565-574, 2017

Yoshida R, Murray MM. Peripheral blood mononuclear cells enhance the anabolic effects of platelet­rich plasma on anterior cruciate ligament fibroblasts; J Orthop Res.31(1):29-34. 2012


FS 552754

Part of Cambridge Business Network